Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors. The main questions it aims to answer are: • Does hydrocortisone replacement therapy reduce the incidence of adrenal insufficiency in participants? Researchers will compare hydrocortisone to a placebo (a look-alike substance that contains no drug) to see if hydrocortisone works to reduce the incidence of adrenal insufficiency. Participants will: * Take or intravenous infusion drug hydrocortisone or a placebo every day for 2 weeks * Visit the clinic three months after surgery for checkups and tests * Keep a diary of their symptoms

NCT Number	NCT06679816
Lead Sponsor	Beijing Tiantan Hospital
Conditions	Pituitary Adenoma, Pituitary Neuroendocrine Tumor
Enrollment	882 participants
Start Date	2024-12-04
Primary Completion	2025-12-31 (estimated)
Study Completion	2026-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-01-14